Operating as a clinical-stage biopharmaceutical enterprise, Synlogic, Inc. is dedicated to the creation and progression of synthetic biotic therapeutics aimed at addressing metabolic and immunological conditions across the United States. Its robust portfolio features multiple drug candidates: SYNB1618 and SYNB1934, both non-systemically absorbed and orally administered, are progressing through Phase II clinical trials for phenylketonuria. Another oral, non-systemic agent, SYNB1353, is designed to treat homocystinuria.